Xian Janssen signs agreement to set up an e-hospital
September 29, 2020 Category Foreign investment, Weekly
On September 24, Xian Janssen Pharmaceutical (Xian Janssen), a pharmaceutical subsidiary of Johnson & Johnson with 35 years of operation in China, announced the signing of a memorandum of cooperation with the First Affiliated Hospital of Xian Jiaotong University to explore the concept of an internet-based and patient-centered “e-hospital”.
This strategic partnership is aimed at delivering a comprehensive new e-hospital model, which will provide virtual health services for patients, initially focusing on oncology (hematology and solid tumors), immunology and pulmonary arterial hypertension. The partnership will also contribute to improving the health of people living in China’s Central and Western regions and support the construction of medical consortiums in Gannan, Gansu provinces. It helps develop their digital infrastructure and ability to introduce high-quality medical services to local people and improve local medical capacity. The cooperation is a pilot between a public hospital and a multinational pharmaceutical company. Xian Janssen will empower internet+ healthcare from treatments to new patient support programs.
There is an increasing demand from patients for online consultations and medical services. For example, patients with pulmonary hypertension face problems to go to medical institutions for treatment and follow-up. Beyond the current internet+ healthcare model mainly involving repeat visits and prescriptions for patients with chronic diseases, the cooperation aims to explore the patient and disease management focused on severe diseases such as oncology, immunology and rare disease. “This partnership demonstrates our commitment to improving the health of Chinese patients above and beyond the work we do to research and develop innovative medicines,” said Asgar Rangoonwala, President of Xian Janssen. “Under the impact of Covid-19, patients cannot access medications offline or seek help from their doctor through traditional channels. By adopting the model of e-hospital, more patients can benefit from medical consultations in a more convenient and efficient way,” Rangoonwala said.
The evolving medical needs and demand for new solutions are especially prominent during and after the outbreak of Covid-19, which has undoubtedly changed the medical needs of patients to a considerable extent. The e-hospital is only part of Xian Janssen’s efforts to better safeguard the health of Chinese people with innovative solutions and technologies. Over the past 35 years, as one of the earliest multinational pharmaceutical companies entering China, Xian Janssen has accompanied and witnessed China’s healthcare reform and the evolution of innovative healthcare development. The company has also been collaborating with digital companies to provide patients with online medical and health services, such as questions about medication, disease consultation, outpatient appointments, and e-prescription. The collaboration between Xian Janssen and AliHealth has benefited more than 15 million Chinese patients so far.
First established in 1985, Xian Janssen has become one of the fastest-growing MNCs with approximately 3,000 employees across the country. In June 2019, following an investment of USD400 million, Xian Janssen opened its new supply chain innovation hub in Xian for commercial production. It sets a new standard in pharmaceutical manufacturing in China and helps to serve the rapidly expanding needs of the country and other markets in the Asia Pacific. The plant features world-class manufacturing technologies and advanced quality control systems. “With our novel innovation strategies and forward-looking investment models, Xian Janssen enables the discovery of game-changing medicines and deployment of a transformational patients’ service model in China to support the fast-changing demands from patients and consumers,” Rangoonwala told the Global Times. “Beyond innovative medicine, we also intend to extend to tailor-made solutions that can optimize patients experience alongside the treatment journey.” Xian Janssen has been launching the Patient Support Program (PSP) in its key therapeutic areas, with features including an online consultation and order system, patient education program and a superior patient experience of using its innovative drugs with special made patient-care packs. The key disease areas include psychiatry, neurology, hematology, immunology, solid tumors, and rare diseases, the Global Times reports.
- KURT VANDEPUTTE (UMICORE) APPOINTED CHAIRMAN OF THE BOARD OF THE FLANDERS-CHINA CHAMBER OF COMMERCE (FCCC)
- Webinar: “Knowing Your Chinese Partner” – May 26, 2021, 10 am – 12 am
- EMA starts rolling review of CoronaVac, WHO approves Sinopharm vaccine for emergency use
- The Global Times warns not to politicize the Comprehensive Agreement on Investment (CAI)
- Hainan to become biggest duty-free market in the world